Spine BioPharma: Funding, Investors & Team (Oct 2026)
Spine BioPharma develops a non-surgical solution for back pain that will eliminate pain and restore functionality, without the use of opioids. The company's pipeline of therapeutic treatments targets the clinical benefits of reducing pain, restoring function and slowing or stopping pathological disease progression. Its mission is to improve the lives of millions of individuals suffering every day from degenerative spine diseases by delivering clinically proven, safe, and effective therapies that inhibit pain and inflammation, and restores quality of life.
Spine BioPharma has raised $41.9M across 4 funding rounds on record, the most recent an undisclosed round of $13.5M announced in Dec 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Spine BioPharma Company Profile and Key Stats
Latest funding round on record: Dec 2024.
Spine BioPharma Funding Rounds
Spine BioPharma raised $13.0M in a Series B announced in Mar 2022.
11 months later, an undisclosed round of $13.0M was announced in Feb 2023.
8 months later, an undisclosed round of $2.4M was announced in Oct 2023.
1.2 years later, an undisclosed round of $13.5M was announced in Dec 2024.
Spine BioPharma Founders and Leadership Team
Contact details for the Spine BioPharma team: 1 of 2 have an email address on file.
Start 14-day free trial →Spine BioPharma Funding Compared to Other Biotechnology Startups
Spine BioPharma's latest round of $13.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Spine BioPharma in Biotechnology and New York
Companies Similar to Spine BioPharma
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Spine BioPharma Funding FAQs
What does Spine BioPharma do?
Spine BioPharma develops a non-surgical solution for back pain that will eliminate pain and restore functionality, without the use of opioids. The company's pipeline of therapeutic treatments targets the clinical benefits of reducing pain, restoring function and slowing or stopping pathological disease progression. Its mission is to improve the lives of millions of individuals suffering every day from degenerative spine diseases by delivering clinically proven, safe, and effective therapies that inhibit pain and inflammation, and restores quality of life.
How much funding has Spine BioPharma raised?
Spine BioPharma has raised $41.9M across 4 rounds on record. The most recent is an undisclosed round of $13.5M announced in Dec 2024.
When did Spine BioPharma last raise funding?
Spine BioPharma's most recent funding round on record is an undisclosed round of $13.5M, announced in Dec 2024.
Who is the CEO of Spine BioPharma?
Marc R Viscogliosi is listed as CEO at Spine BioPharma.
Where is Spine BioPharma headquartered?
Spine BioPharma is based in New York, United States.
How many employees does Spine BioPharma have?
Spine BioPharma is in the 11-50 employee band.
How does Spine BioPharma's funding compare to other Biotechnology startups?
Spine BioPharma's latest round of $13.5M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Spine BioPharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Spine BioPharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.